The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Oct 12, 2023
Trial Information
Current as of August 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Referred for clinically indicated CFT
- Exclusion Criteria:
- • Not willing to provide informed consent
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Enschede, , Netherlands
Eindhoven, , Netherlands
Arnhem, , Netherlands
Utrecht, , Netherlands
Breda, , Netherlands
Rotterdam, , Netherlands
Leeuwarden, , Netherlands
Venlo, , Netherlands
Amsterdam, , Netherlands
Maastricht, , Netherlands
Hilversum, , Netherlands
Nijmegen, , Netherlands
Heerlen, , Netherlands
Amsterdam, , Netherlands
Den Haag, , Netherlands
Nijmegen, Gelderland, Netherlands
Tilburg, , Netherlands
Patients applied
Trial Officials
Peter Damman
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported